nih studi public detail benefit gilead
remdesivir chang fve
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim apr
price data may
rate updat may
currenc amount express
methodolog valu compani
detail result nih-sponsor studi
gilead remdesivir treatment coronaviru
studi publish new england journal
medicin may make chang
gilead fair valu estim public offer
detail beyond top-lin posit result
studi announc april key remdesivir
emerg use author food drug
administr may still model potenti peak
sale drug billion
commerci sale start second half
hospit rapidli burn gilead donat
suppli drug gilead expect data anoth
placebo-control studi -- one focus hospit
patient moder diseas -- june
remdesivir exampl sort innov antivir
medicin come gilead pipelin creat
portfolio hiv hepat drug support wide
moat think drug yet demonstr
larg sustain impact gilead futur
author discuss think remdesivir help
treatment patient suffici
stop patient death sever case
drug like lilli olumi studi
combin remdesivir still think rapid
progress right vaccin assum timelin
broad vaccin avail first half
vaccin high-risk individu late
discuss may report relax
coronaviru lockdown move slowli nimbl
look even achiev today two week
ago given combin sever piec recent news
includ posit top-line data phase
studi show solid initi safeti product
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit
pend forty-seven acquisit boost gilead exposur cell therapi
non-cel therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
trial encouragingli author note data
may fit result publish articl data
april
neutral antibodi vaccin phase start
pois juli see may note tie vaccin maker
cansino biolog public phase data vaccin
lancet may show immedi side effect
antibodi t-cell respons astrazeneca/
oxford announc acceler develop
deliveri timelin vaccin phase data
earli august hundr million dose potenti
deliv start septemb see may
dive data patient overal recoveri
time significantli
patient take
remdesivir among given placebo day
day improv mortal rate
encourag statist signific
start studi patient
spectrum diseas sever roughli patient
requir oxygen patient requir
supplement oxygen non-invasive ventil
high-flow oxygen requir mechan
ventil blood oxygen pump four group
patient appear differ level respons
remdesivir best improv respons
middl spectrum patient receiv oxygen
improv recoveri time appar improv
patient oxygen non-invasive ventil
respect improv patient
mechan ventil slightli smaller group
patient data patient mortal rate
also dramat differ group patient
receiv oxygen ordin score baselin
mortal remdesivir placebo
author hypothes larger appar benefit
patient receiv oxygen could simpli due larger
size group expect see updat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
